SG Americas Securities LLC Has $62,000 Holdings in VBI Vaccines Inc. (NASDAQ:VBIV)

SG Americas Securities LLC boosted its stake in VBI Vaccines Inc. (NASDAQ:VBIVGet Rating) by 91.9% in the second quarter, HoldingsChannel.com reports. The firm owned 77,111 shares of the biopharmaceutical company’s stock after buying an additional 36,923 shares during the period. SG Americas Securities LLC’s holdings in VBI Vaccines were worth $62,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Engineers Gate Manager LP acquired a new stake in VBI Vaccines during the 1st quarter worth about $26,000. Russell Investments Group Ltd. acquired a new stake in VBI Vaccines during the 1st quarter worth about $34,000. E Fund Management Co. Ltd. grew its holdings in VBI Vaccines by 98.1% during the 1st quarter. E Fund Management Co. Ltd. now owns 53,148 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 26,320 shares during the period. OLD National Bancorp IN acquired a new stake in VBI Vaccines during the 2nd quarter worth about $89,000. Finally, Qube Research & Technologies Ltd grew its holdings in VBI Vaccines by 26.3% during the 1st quarter. Qube Research & Technologies Ltd now owns 88,895 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 18,500 shares during the period. 39.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Raymond James downgraded VBI Vaccines from a “strong-buy” rating to an “outperform” rating and decreased their price target for the stock from $5.00 to $2.00 in a report on Friday, November 11th.

VBI Vaccines Price Performance

VBIV stock opened at $0.62 on Friday. The stock has a market capitalization of $160.87 million, a PE ratio of -1.45 and a beta of 1.83. The company’s 50-day moving average is $0.70 and its 200-day moving average is $0.86. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.77 and a quick ratio of 2.61. VBI Vaccines Inc. has a 1 year low of $0.56 and a 1 year high of $3.42.

VBI Vaccines Profile

(Get Rating)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

Featured Articles

Want to see what other hedge funds are holding VBIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VBI Vaccines Inc. (NASDAQ:VBIVGet Rating).

Institutional Ownership by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.